And in the validation cohort, 74 cases (30.6%) were HR-positive/HER2-negative, 52 cases (21.5%) were HR-positive/HER2-positive, 59 cases (24.4%) were HR-negative/HER2-positive, and 57 cases (23.6%) were triple negative breast cancer (TNBC) (Supplementary Table 1). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.